Fund Holdings — Lynx1 Capital Management LP

Total Portfolio Value
$491.30M
Total Bought
$38.64M
Total Sold
$86.65M
Net Transaction
-$48.01M
Filing Period:
Securities
▲▼
SharesValue ($K)
Q2 2025
▲▼
Q3 2025
▲▼
Change
▲▼
Q2 2025
▲▼
Q3 2025
▲▼
Weight (%)
▲▼
Change
▲▼
MERUS N V1,568,8411,534,141-34,70082,521144,43929.40%+61,918
STOKE THERAPEUTICS INC(STOK)5,404,6745,404,674061,343109,88122.37%+48,538
GH RESEARCH PLC(GHRS)6,746,9518,601,189+1,854,23882,245104,31221.23%+22,066
PROTAGONIST THERAPEUTICS INC733,014700,014-33,00040,51446,5029.47%+5,988
C4 THERAPEUTICS INC(CCCC)7,098,1337,098,133010,15015,7583.21%+5,608
ADC THERAPEUTICS SA(ADCT)01,325,848+1,325,84805,3031.08%+5,303
PASSAGE BIO INC(PASG)0623,704+623,70405,0081.02%+5,008
DENALI THERAPEUTICS INC(DNLI)0261,687+261,68703,8000.77%+3,800
TSCAN THERAPEUTICS INC(TCRX)7,857,3477,857,347011,39314,3002.91%+2,907
PRECISION BIOSCIENCES INC(DTIL)1,036,0511,042,596+6,5454,3515,7551.17%+1,404
CULLINAN THERAPEUTICS INC(CGEM)4,400,8425,766,090+1,365,24833,13834,1936.96%+1,055
DESIGN THERAPEUTICS INC(DSGN)65,95465,95402224970.10%+274
ASSEMBLY BIOSCIENCES INC10,3660-10,3661880—-188
IBIO INC(IBIO)1,538,5731,055,897-482,6761,1748740.18%-300
NEUPHORIA THERAPEUTICS INC45,8060-45,8063250—-325
UPSTREAM BIO INC(UPB)219,2470-219,2472,4070—-2,407
PASSAGE BIO INC(PASG)9,256,9530-9,256,9533,7060—-3,706
ALLOGENE THERAPEUTICS INC11,057,009546,119-10,510,89012,4946770.14%-11,817
Page 1 of 1
Lynx1 Capital Management LP — 13F Holdings — Q3 2025 | TickerTrail